Radiogenesis is designing the next generation of targeted radioligand therapies.

Radiopharmaceuticals represent one of the most vital frontiers in oncology. Computational drug design can fundamentally transform how these medicines are created.

Early approvals demonstrate that targeted radiotherapeutic drugs, which deliver nuclear radiation directly to tumors, can significantly improve patient outcomes in cancers that are otherwise hard to treat. Currently, this modality is only available for 2 tumor types, but many cancer indications remain unsolved. Hundreds of thousands of patients are waiting for better treatment options.

The bottleneck? Discovering, pairing, and optimizing these therapies is still slow, fragmented, and expensive. Radiogenesis is built to solve that.

Instead of discovering ligands first, and attempting to retrofit complex radiochemistry later, our purpose-built AI platform optimizes the entire molecular construct. By combining advances in generative artificial intelligence, protein engineering, radiochemistry, cancer biology and physics, we accelerate the development of targeted therapies for patients with metastatic cancers.

Our vision is simple: bring better radiotherapeutics to more patients, faster.

Radiogenesis

Org chart

Teams

Offices

Radiogenesis

Org chart

Teams

Offices

Related companies